Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Nubeqa (darolutamide)
pCPA File Number:
21244
Negotiation Status:
Concluded with an LOI
Indication(s):
non-metastatic castrate resistant prostate cancer
Sponsor/Manufacturer:
Bayer Inc.
CADTH Project Number:
pCODR 10196
pCPA Engagement Letter Issued:
2020-10-23
Negotiation Process Concluded:
2021-02-18